000597.SZ
东北制药
SZSE · Healthcare · C 制造业 · CN
CNY 4.88
−2.59%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
6.0x
Market Cap
CNY 6.96B
MomentumView details →
1D Return
−2.59%
YTD Return
−8.43%
RSI (14)
45.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
6.0x
Market Cap
CNY 6.96B
RSI (14)
45.7
MomentumView details →
1D Return
−2.59%
YTD Return
−8.43%
Similar companies
Latest newsMore news →
On September 1, 2026, after market close, 12 A-share listed companies including Yiatong, Henggong Precision, Weihong, Jiuzhou Yigui, Zhongman Petroleum, Shanghai Xiba, Gongdong Medical, Jincang Group, Northeast Pharmaceutical, Kingmed Diagnostics, Yongzhen, and Fuchun Dyeing disclosed plans to reduce holdings, while Huaxia Eye Hospital disclosed a plan to increase holdings.3d agoNortheast Pharmaceutical director Guo Jianmin plans to sell up to 0.0560% of the company's shares within three months starting 15 trading days after September 2, 2026.4d agoNortheast Pharmaceutical received approval from the National Medical Products Administration for its marketing application of the chemical active pharmaceutical ingredient baloxavir marboxil, valid until July 19, 2031.45d ago